key: cord-0856768-cu7ik4np
authors: Zhang, L.‐w.; Wang, W.‐j.; Li, C.‐h.; Chen, T.
title: Erythema multiforme after SARS‐CoV‐2 vaccine
date: 2021-10-05
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.17689
sha: 2b2900a84d08bfadb48148e229b2ee5480fab271
doc_id: 856768
cord_uid: cu7ik4np

A 46-year-female presented with a one-week history of multiple erythema and blisters with pruritus on the extremities. She had received both doses of the SARS-CoV-2 vaccine (CoronaVac developed by Sinovac Life Sciences, Beijing, China) which is an inactivated vaccine. She had no adverse reactions after the first dose.

Dear Editor, A 46-year-female presented with a 1-week history of multiple erythema and blisters with pruritus on the extremities. She had received both doses of the SARS-CoV-2 vaccine (Corona Vac developed by Sinovac Life Sciences, Beijing, China), which is an inactivated vaccine. She had no adverse reactions after the first dose. The cutaneous lesions started 4 days after the second dose. She denied systemic diseases, medication history and medicine or food allergic history. Physical examination showed multiple circular erythema and blisters with classic target lesions on the distal extremities ( Fig. 1 ). Multiple erosions involved her lip and oral mucosa (Fig. 2) . Laboratory tests including blood routine, hepatic and renal function, T. pallidum particle assay, and HIV antibody serology test were normal or negative. The patient was diagnosed with erythema multiforme (EM) and treated with oral loratadine, rinsing with compound chlorhexidine gargle, and topical corticosteroids. The lesions and symptoms were completely relieved after 2 weeks. Erythema multiforme is an acute self-limited immune-mediated mucocutaneous disorder, and occasionally occurs with visceral involvement in severe patients. The lesions are distributed preferentially on the distal extremities with classic target lesions and may accompany a mucosal injury. Potential triggering factors of EM include infections (especially herpes simplex virus infections), drugs (containing vaccine), topical agents, and some systemic diseases.

With the worldwide vaccination campaign against the COVID-19 pandemic continuing, increasing cutaneous reactions after the SARS-CoV-2 vaccine have been reported. The most common reported cutaneous reactions included urticaria, local injection-site reaction and morbilliform rash. 1 Other cutaneous reactions included delayed large local reaction, swelling, erythema, painful/itchy sensation, erythromelalgia, a flare of an existing dermatologic condition, vesicular, chilblains, zoster, angioedema, pityriasis rosea, filler reaction, vasculitis, contact dermatitis, rash in a breastfed infant, petechiae, lichen planus and EM. [1] [2] [3] [4] These reported cutaneous reactions were mainly associated with mRNA SARS-CoV-2 vaccine. There are few cutaneous reactions reported about inactivated SARS-CoV-2 vaccine in the literature.

In conclusion, cutaneous adverse reactions from the SARS-CoV-2 vaccine were very rare, mild and generally rapid spontaneous resolution. 4 We should advance notice and reassure the vaccinator. Nevertheless, these adverse events and others should not discourage vaccination against a life-threatening virus.

The patients in this manuscript have given written informed consent to the publication of their case details. This content has not been published, nor has it been submitted for publication elsewhere. On behalf of all the contributors, Tao Chen will act as guarantor and will correspond with the journal from this point 

Localized cutaneous reaction to an mRNA COVID-19 vaccine

New-onset cutaneous lichen planus triggered by COVID-19 vaccination

Erythema multiforme after Corona-Vac vaccination

Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series